Profil
Rebecca Cohen is currently working as an Investor Relations Contact at Ikena Oncology, Inc. Previously, she worked as the Head-Corporate & Investor Relations at SQZ Biotechnologies Co. from 2017 to 2018.
She also served as an IR & Corporate Communications Contact at Epizyme, Inc.
Postes actifs de Rebecca Cohen
| Sociétés | Poste | Début |
|---|---|---|
| IKENA ONCOLOGY, INC. | Investor Relations Contact | - |
Anciens postes connus de Rebecca Cohen
| Sociétés | Poste | Fin |
|---|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Investor Relations Contact | 01/07/2018 |
| EPIZYME, INC. | Public Communications Contact | 01/05/2016 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| IKENA ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
